echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > FDA approves emergency use of second oral drug to treat COVID-19

    FDA approves emergency use of second oral drug to treat COVID-19

    • Last Update: 2022-02-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On December 23, local time, the U.


    The U.


    The statement said that monabiravir is a prescription drug, and patients must take it as soon as possible after the diagnosis of new coronary pneumonia, start taking it within 5 days after the onset of symptoms of new coronary pneumonia, and use it continuously for no more than 5 days


    Monabiravir should not be used in people under the age of 18 because the drug may affect bone and cartilage growth, the statement said


    Cavazzoni, director of the FDA's Center for Drug Evaluation and Research, said that as new mutant strains continue to emerge, it is critical to expand the available options for treating new coronavirus infections in the United States through emergency use authorization, while continuing to evaluate the safety of these options.


    The U.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.